蛋白激酶A调节亚基a1抗体

我公司供应质优价美的科研产品，蛋白激酶A调节亚基a1抗体产品质量保证，提供蛋白激酶A调节亚基a1抗体技术支持，有任何质量问题可免费包退包换，欢迎来电咨询！我们将竭诚为您服务！

英文名称  Anti-PRKAR1

中文名称  蛋白激酶A调节亚基a1抗体

别    名  Protein Kinase A regulatory subunit I alpha; cAMP dependent protein kinase regulatory subunit alpha 1; cAMP dependent protein kinase regulatory subunit RIalpha; cAMP dependent protein kinase type I alpha regulatory chain; cAMP dependent protein kinase type I alpha regulatory subunit; CAR; CNC 1; CNC; CNC1; DKFZp779L0468; MGC17251; PKA RIA; PKR 1; PKR1; PPNAD 1; PPNAD1; PRKAR 1; PRKAR1; PRKAR1A; Protein kinase A type 1a regulatory subunitv Protein kinase cAMP dependent regulatory type I alpha; Tissue specific extinguisher 1; TSE 1; TSE1; KAP0_HUMAN.

浓    度  1mg/1ml

规 格  0.1ml/100μg  0.2ml/200μg

抗体来源  Rabbit  

克隆类型  polyclonal

交叉反应  Human, Mouse, Rat

产品类型  一抗    

研究领域  肿瘤 细胞生物 免疫学 转录调节因子 激酶和磷酸酶  

蛋白分子量  predicted molecular weight: 43kDa

性    状  Lyophilized or Liquid

蛋白激酶A调节亚基a1抗体的功能抗体的主要功能是与抗原（包括外来的和自身的）相结合，从而有效地清除侵入机体内的微生物、寄生虫等异物，抗体（antibody）是一种应答抗原产生的、可与抗原特异性结合的蛋白质。每种抗体与特定的抗原决定基结合。这种结合可以使抗原失活，也可能无效但有时也会对机体造成病理性损害，如抗核抗体、抗双链DNA抗体、抗甲状腺球蛋白抗体等一些自身抗体的产生，对人体可造成危害。

免 疫 原  KLH conjugated synthetic peptide derived from human Protein Kinase A regulatory subunit I alpha

亚    型  IgG

纯化方法  affinity purified by Protein A

储 存 液  0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

产品应用   WB=1:100-500  ELISA=1:500-1000  IP=1:20-100  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500

（石蜡切片需做抗原修复）

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

产品介绍 cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. This gene encodes one of the regulatory subunits. This protein was found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Mutations in this gene cause Carney complex (CNC). This gene can fuse to the RET protooncogene by gene rearrangement and form the thyroid tumor-specific chimeric oncogene known as PTC2. A nonconventional nuclear localization sequence (NLS) has been found for this protein which suggests a role in DNA replication via the protein serving as a nuclear transport protein for the second subunit of the Replication Factor C (RFC40). Three alternatively spliced transcript variants encoding the same protein have been observed. [provided by RefSeq, Jul 2008].

Function : Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.

Subunit : The inactive holoenzyme is composed of two regulatory chains and two catalytic chains. Activation by cAMP releases the two active catalytic monomers and the regulatory dimer. PRKAR1A also interacts with RFC2; the complex may be involved in cell survival. Interacts with AKAP4. Interacts with RARA; the interaction occurs in the presence of cAMP or FSH and regulates RARA transcriptional activity. Interacts with the phosphorylated form of PJA2. Interacts with CBFA2T3 (By similarity). Interacts with PRKX; regulates this cAMP-dependent protein kinase.

Tissue Specificity : Four types of regulatory chains are found: I-alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible.

Post-translational modifications : The pseudophosphorylation site binds to the substrate-binding region of the catalytic chain, resulting in the inhibition of its activity.

DISEASE : Defects in PRKAR1A are the cause of Carney complex type 1 (CNC1) [MIM:160980]. CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.

Defects in PRKAR1A are the cause of intracardiac myxoma (INTMYX) [MIM:255960]. Inheritance is autosomal recessive.

Defects in PRKAR1A are the cause of primary pigmented nodular adrenocortical disease type 1 (PPNAD1) [MIM:610489]. Primary pigmented nodular adrenocortical disease is a rare bilateral adrenal defect causing ACTH-independent Cushing syndrome. Macroscopic appearance of the adrenals is characteristic with small pigmented micronodules observed in the cortex. PPNAD1 is most often diagnosed in patients with Carney complex, but it can also be observed in patients without other manifestations or familial history.

蛋白激酶A调节亚基a1抗体Similarity : Belongs to the cAMP-dependent kinase regulatory chain family.

Contains 2 cyclic nucleotide-binding domains.

Database links : UniProtKB/Swiss-Prot: P10644.1